About CureVac N.V.
https://www.curevac.comCureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
CEO
Alexander Zehnder
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 7
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
GLAZER CAPITAL, LLC
Shares:4.55M
Value:$21.19M
ALPINE ASSOCIATES MANAGEMENT INC.
Shares:2.3M
Value:$10.7M
BLACKROCK INC.
Shares:2.25M
Value:$10.5M
Summary
Showing Top 3 of 108
About CureVac N.V.
https://www.curevac.comCureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $493.9M ▲ | $-32.61M ▼ | $338.04M ▲ | 68.44% ▲ | $1.5 ▲ | $0 ▲ |
| Q2-2025 | $1.25M ▲ | $60.78M ▲ | $-59.56M ▼ | -4.78K% ▲ | $-0.26 ▼ | $-54.99M ▼ |
| Q1-2025 | $893K ▼ | $54.74M ▼ | $-52.08M ▼ | -5.83K% ▼ | $-0.23 ▼ | $-46.74M ▼ |
| Q4-2024 | $14.47M ▼ | $56.74M ▼ | $-32.76M ▼ | -226.42% ▼ | $-0.15 ▼ | $-34.89M ▼ |
| Q3-2024 | $493.9M | $103.59M | $338.04M | 68.44% | $1.51 | $375.23M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $395.81M ▼ | $688.88M ▼ | $102.51M ▲ | $586.37M ▼ |
| Q1-2025 | $442.09M ▼ | $742.27M ▼ | $95.58M ▼ | $646.69M ▼ |
| Q4-2024 | $485.37M ▼ | $802.83M ▼ | $106.22M ▼ | $696.61M ▼ |
| Q3-2024 | $554.92M ▲ | $854.19M ▲ | $129.49M ▼ | $724.7M ▲ |
| Q2-2024 | $202.51M | $556.84M | $180.3M | $376.53M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-59.97M ▼ | $-42.06M ▼ | $-1.55M ▼ | $-1.31M ▲ | $-45.63M ▼ | $-43.62M ▼ |
| Q1-2025 | $-51.66M ▼ | $-41.37M ▲ | $-511K ▲ | $-1.31M ▼ | $-43.42M ▲ | $-41.88M ▲ |
| Q4-2024 | $-38.56M ▼ | $-66.56M ▼ | $-2.57M ▲ | $-1.28M ▲ | $-69.11M ▼ | $-69.13M ▼ |
| Q3-2024 | $370.57M ▲ | $354.08M ▲ | $-3.3M ▲ | $-1.5M ▼ | $348.35M ▲ | $350.78M ▲ |
| Q2-2024 | $-72.91M | $-89.11M | $-7.49M | $-1.22M | $-97.64M | $-96.25M |
CEO
Alexander Zehnder
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 7
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
GLAZER CAPITAL, LLC
Shares:4.55M
Value:$21.19M
ALPINE ASSOCIATES MANAGEMENT INC.
Shares:2.3M
Value:$10.7M
BLACKROCK INC.
Shares:2.25M
Value:$10.5M
Summary
Showing Top 3 of 108